ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing other therapeutic DC vaccines, such as ICT-140 for ovarian cancer; and ICT-121 to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.
As of January 27th 2017, $IMUC looks to be bullish, for a 1 to 4 week hold. A purchase at a price between $2.25 and $2.70 is safe and could bring you returns between 25% and 40%% in the next 30 days. If IMUC breaks out above $3.20, we could see if reaching the $6.80 level within the same week.
Be sure you place a stop loss at 10% below you buy price, and don’t be greedy, a consistent 10% to 15% per month can help dealing with losses and sometimes help bring in more profits.
Also, please keep in mind we are not offer trading advice, we are just sharing an idea.
For real stock trading advice you should contact a professional financial adviser.